The UK health minister has announced plans to label all British prescription medicines with their cost to the taxpayer.
Toronto-based Attix Pharmaceuticals has received a US FDA warning letter after an inspection from November and a lack of corrective actions in the company’s response to the FDA.
MHRA, the UK pharma regulator, says its staff cuts over the next three years will not impact its work with pharma.
Manufacturing operations at an Actavis legacy site in Iceland will cease and products will be transferred out the country from 2016, Allergan has announced.
Capsugel has pledged to continue investing internally in drug delivery R&D after completing construction of a spray-dried dispersion (SDD) commercial manufacturing site in Oregon.
Hospira has begun commercial production at a sterile injectable plant in India hit with several 483 forms after the US FDA deemed the site ‘acceptable.’